2023
Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial
Patel K, Lansky A, Kelbaek H, Xu B, Van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A. Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial. European Heart Journal 2023, 44: ehad655.1494. DOI: 10.1093/eurheartj/ehad655.1494.Peer-Reviewed Original ResearchAcute coronary syndromeChronic coronary syndromeProbable stent thrombosisCoronary syndromeStent thrombosisFIREHAWK stentLesion failureClinical presentationLong-term PCI outcomesPatient-oriented composite endpointTarget lesion revascularisationMajor adverse eventsLong-term outcomesLong-term safetyCCS cohortComer patientsID-TLRLesion revascularisationCCS patientsOpen labelAdverse eventsBaseline characteristicsACS cohortComposite endpointComers trial
2013
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013, 9: 75-83. PMID: 23685298, DOI: 10.4244/eijv9i1a12.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedAnalysis of VarianceAntineoplastic AgentsChinaChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansLeast-Squares AnalysisMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsIschaemia-driven target lesion revascularisationStent late lumen lossTarget vessel myocardial infarctionLate lumen lossTarget lesion failureSingle de novo coronary lesionsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsPrimary endpointCardiac deathI trialNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentSingle de novo native coronary lesionsDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsNine monthsNative coronary lesionsProbable stent thrombosisTarget lesion revascularisationVessel myocardial infarctionSirolimus-eluting stentsNon-inferiority trialLesion revascularisationEES groupDrug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials
Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, Meier P. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart 2013, 99: 327. PMID: 23335497, DOI: 10.1136/heartjnl-2012-302945.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsDrug-eluting balloonsDrug-eluting balloon angioplastyBalloon angioplastyStent restenosisStent thrombosisMyocardial infarctionRelative riskSegment restenosisTreatment optionsSystematic reviewIncidence of MIRisk of STAdverse cardiac eventsPooled relative riskPlain balloon angioplastyOptimal treatment optionsPromising treatment optionDrug-eluting stentsRandom-effects modelLesion revascularisationCardiac eventsCoronary angioplastyMain endpointClinical trials